COVID-19 Vaccination and Hospitalization Among Persons Living With Diagnosed HIV in New York State.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
received:
21
10
2022
accepted:
09
02
2023
medline:
26
6
2023
pubmed:
1
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Persons living with diagnosed HIV (PLWDH) have higher COVID-19 diagnoses rates and poorer COVID-19-related outcomes than persons living without diagnosed HIV. The intersection of COVID-19 vaccination status and likelihood of severe COVID-19 outcomes has not been fully investigated for PLWDH. New York State (NYS). We matched HIV surveillance, immunization, and hospitalization databases to compare COVID-19 vaccination and COVID-19-related hospitalizations among PLWDH during B.1.617.2 (Delta) and B.1.1.529 (Omicron) predominance. Through March 4, 2022, 69,137 of the 101,205 (68%) PLWDH were fully vaccinated or boosted for COVID-19. PLWDH who were virally suppressed or in care were more often to be fully vaccinated or boosted compared with PLWDH who were not virally suppressed (77% vs. 44%) or without evidence of care (74% vs. 33%). Overall hospitalization rates were lower among virally suppressed PLWDH. During Delta predominance, PLWDH with any vaccination history who were in care had lower hospitalization rates compared with those not in care; during Omicron predominance, this was the case only for boosted PLWDH. Approximately 28% (28,255) of PLWDH in NYS remained unvaccinated for COVID-19, a rate roughly double of that observed in the overall adult NYS population. PLWDH of color were more often than non-Hispanic White persons to be unvaccinated, as were the virally unsuppressed and those without evidence of HIV-related care, threatening to expand existing disparities in COVID-19-related outcomes. Vaccination was protective against COVID-19-related hospitalizations for PLWDH; however, differences in hospitalization rates between fully vaccinated and unvaccinated PLWDH were smaller than those among all New Yorkers.
Sections du résumé
BACKGROUND
Persons living with diagnosed HIV (PLWDH) have higher COVID-19 diagnoses rates and poorer COVID-19-related outcomes than persons living without diagnosed HIV. The intersection of COVID-19 vaccination status and likelihood of severe COVID-19 outcomes has not been fully investigated for PLWDH.
SETTING
New York State (NYS).
METHODS
We matched HIV surveillance, immunization, and hospitalization databases to compare COVID-19 vaccination and COVID-19-related hospitalizations among PLWDH during B.1.617.2 (Delta) and B.1.1.529 (Omicron) predominance.
RESULTS
Through March 4, 2022, 69,137 of the 101,205 (68%) PLWDH were fully vaccinated or boosted for COVID-19. PLWDH who were virally suppressed or in care were more often to be fully vaccinated or boosted compared with PLWDH who were not virally suppressed (77% vs. 44%) or without evidence of care (74% vs. 33%). Overall hospitalization rates were lower among virally suppressed PLWDH. During Delta predominance, PLWDH with any vaccination history who were in care had lower hospitalization rates compared with those not in care; during Omicron predominance, this was the case only for boosted PLWDH.
CONCLUSIONS
Approximately 28% (28,255) of PLWDH in NYS remained unvaccinated for COVID-19, a rate roughly double of that observed in the overall adult NYS population. PLWDH of color were more often than non-Hispanic White persons to be unvaccinated, as were the virally unsuppressed and those without evidence of HIV-related care, threatening to expand existing disparities in COVID-19-related outcomes. Vaccination was protective against COVID-19-related hospitalizations for PLWDH; however, differences in hospitalization rates between fully vaccinated and unvaccinated PLWDH were smaller than those among all New Yorkers.
Identifiants
pubmed: 36853763
doi: 10.1097/QAI.0000000000003177
pii: 00126334-990000000-00193
pmc: PMC10179975
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
92-100Subventions
Organisme : FIC NIH HHS
ID : D43 TW011532
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
New York State Department of Health. COVID-19 data in New York. https://coronavirus.health.ny.gov/covid-19-data-new-york . Accessed April 28, 2022.
Centers for Disease Control and Prevention. COVID data tracker. US department of health and human services, CDC. https://covid.cdc.gov/covid-data-tracker . Accessed January 6, 2023.
Centers for Disease Control and Prevention. HIV surveillance report, 2020. Vol 33; 2022. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Accessed January 6, 2023.
New York State Department of Health. Vaccination progress to date. https://coronavirus.health.ny.gov/vaccination-progress-date . Accessed August 4, 2022.
Leon TM, Dorabawila V, Nelson L, et al. COVID-19 cases and hospitalizations by COVID-19 vaccination status and previous COVID-19 diagnosis - California and New York, May-November 2021. MMWR Morb Mortal Wkly Rep. 2022;71:125–131.
Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status - New York, May 3-July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1306–1311.
Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA 2021;23326:2043–2054.
Taylor CA, Whitaker M, Anglin O, et al. COVID-19-Associated hospitalizations among adults during SARS-CoV-2 Delta and Omicron variant predominance, by race/ethnicity and vaccination status - COVID-NET, 14 states, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:466–473.
Modes ME, Directo MP, Melgar M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance - one hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217–223.
Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV 2021;8:e24–e32.
Braunstein SL, Lazar R, Wahnich A, et al . Coronavirus disease 2019 (COVID-19) infection among people with human immunodeficiency virus in New York city: a population-level analysis of linked surveillance data. Clin Infect Dis. 2020;72:e1021–e1029.
Geretti AM, Stockdale AJ, Kelly SH, et al. Outcomes of coronavirus disease 2019 (COVID-19) related hospitalization among people with human immunodeficiency virus (HIV) in the ISARIC world health organization (WHO) clinical characterization protocol (UK): a prospective observational study. Clin Infect Dis. 2020;73:e2095–e2106.
Tesoriero JM, Swain CAE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York state. JAMA Netw Open 2021;4:e2037069.
Boulle A, Davies MA, Hussey H, et al. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the western cape province, South Africa. Clin Infect Dis. 2021;73:e2005–e2015.
World Health Organization. Clinical Features and Prognostic Factors of COVID-19 in People Living with HIV Hospitalized with Suspected or Confirmed SARS-CoV-2 Infection; 2021:2021. https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1
Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV 2021;8:e690–e700.
Rosenthal EM, Rosenberg ES, Patterson W, et al. Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State. PLoS One 2022;17:e0268978.
New York State Department of Health. Covid-19 vaccine: frequently asked questions. https://covid19vaccine.health.ny.gov/frequently-asked-questions-0 . Accessed January 6, 2023.
Tesoriero JM, Patterson W, Daskalakis D, et al. Notes from the field: COVID-19 vaccination among persons living with diagnosed HIV infection - New York, October 2021. MMWR Morb Mortal Wkly Rep. 2022;71:182–184.
Rosenberg ES, Dorabawila V, Easton D, et al. Covid-19 vaccine effectiveness in New York state. N Engl J Med. 2022;386:116–127.
Di Fusco M, Moran MM, Cane A, et al. Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. J Med Econ. 2021;24:1248–1260.
Suleyman G, Fadel R, Brar I, et al. Risk factors associated with hospitalization and death in COVID-19 breakthrough infections. Open Forum Infect Dis. 2022;9:ofac116.
Coburn SB, Humes E, Lang R, et al. Analysis of postvaccination breakthrough COVID-19 infections among adults with HIV in the United States. JAMA Netw Open 2022;5:e2215934.
Lang R, Humes E, Coburn SB, et al. Analysis of severe illness after postvaccination COVID-19 breakthrough among adults with and without HIV in the US. JAMA Netw Open 2022;5:e2236397.
Sun J, Zheng Q, Madhira V, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182:153–162.
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–577.
gov NY. Governor Cuomo Announces List of Comorbidities and Underlying Conditions Eligible for COVID-19 Vaccine Starting February 15. Updated February 5, 2021. https://www.governor.ny.gov/news/governor-cuomo-announces-list-comorbidities-and-underlying-conditions-eligible-covid-19-vaccine . Accessed May 25, 2022.
Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among Black patients and white patients with covid-19. N Engl J Med. 2020;382:2534–2543.
Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and people living with human immunodeficiency virus: outcomes for hospitalized patients in New York city. Clin Infect Dis. 2020;1271:2933–2938.
Meyerowitz EA, Kim AY, Ard KL, et al. Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV. AIDS 2020;1034:1781–1787.
Kamis KF, Barbera L, Abdo M, et al. Risk factors for hospitalization in people with HIV and COVID-19. JAIDS 2021;88:e22.
Kalichman SC, Eaton LA, Berman M, et al. Intersecting pandemics: impact of SARS-CoV-2 (COVID-19) protective behaviors on people living with HIV, Atlanta, Georgia. JAIDS 2020;85:66–72.
Ambrosioni J, Blanco JL, Reyes-Urueña JM, et al. Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV 2021;8:e294–e305.
Johnson AG, Amin AB, Ali AR, et al. COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of Delta and Omicron variant emergence - 25 U.S. Jurisdictions, April 4-december 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138.
Centers for Disease Control and Prevention. People with Certain Medical Conditions. Updated May 2, 2022. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html . Accessed May 25, 2022.
Dai H, Saccardo S, Han MA, et al. Behavioural nudges increase COVID-19 vaccinations. Nature 2021;597:404–409.
Centers for Disease Control and Prevention. Data to care. https://www.cdc.gov/hiv/effective-interventions/treat/data-to-care/index.html?Sort=Title%3A%3Aasc&Intervention%20Name=Data%20to%20CareName%3DData%20to%20Care . Accessed July 22, 2022.
Holtgrave DR, Barranco MA, Tesoriero JM, et al . Assessing racial and ethnic disparities using a COVID-19 outcomes continuum for New York State. Ann Epidemiol. 2020;48:9–14.